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Background: Oxidation and inflammation play significant roles in the pathogenesis of coronary artery diseases.
Monocyte count to high-density lipoprotein (HDL) cholesterol ratio (MHR) is a new marker and has revealed as an
indicator of inflammation in the literature. The present study aimed to search the effect of MHR on in-stent
restenosis (ISR) in patients with stable or unstable angina pectoris undergoing bare-metal stent (BMS) implantation.
Methods: A total of 468 consecutive stable or unstable angina pectoris patients (mean age 60.3 ± 10.1 and 70 %
men) who had undergone successful BMS implantation were included the study. Serum samples were obtained
before the procedure.
Results: The mean period between two coronary angiography procedures was 14 ± 7.9 months. The baseline MHR
levels were significantly higher in patients that had ISR (odds ratio, 3.64; 95 % confidence interval, 2.45- 4.84; P < 0.
001). Stent diameter, the time between the two coronary angiographic studies, uric acid and MHR levels emerged
as independent predictors of ISR.
Conclusions: Our results indicate that elevated MHR is an independent and powerful predictor of ISR in patients
with stable or unstable angina pectoris who underwent successful BMS implantation.
Keywords: Novel marker, Monocyte /HDL cholesterol ratio, Instent restenosis, Bare metal
Background
Despite new medications and techniques, in-stent resten-
osis (ISR) after successful percutaneous coronary interven-
tions remains a major problem and limiting the efficacy of
the procedure [1]. Inflammation, extracellular matrix re-
modeling, and smooth muscle cell proliferation are reasons
for neo-intimal hyperplasia and restenosis [2, 3].
Circulating monocytes as a source of various cytokines
and molecules, interact with platelets and endothelial cells
and leading to aggravation of inflammatory, pro-
thrombotic pathways [4]. High-density lipoprotein (HDL)
defuse these pro-inflammatory and pro-oxidant effects of
monocytes by inhibiting the migration of macrophages and
oxidation of the low-density lipoprotein (LDL) molecules
as well as promoting the efflux of cholesterol from these
cells [5].
Monocyte count to HDL cholesterol ratio (MHR) has
been reported as a new prognostic marker in cardiovas-
cular diseases [6–8]. It has been revealed that MHR is
related with major cardiovascular adverse events
(MACE) including stent thrombosis and mortality after
primary percutaneous coronary intervention (PCI) in
ST-segment elevation myocardial infarction (STEMI) pa-
tients, [9]. To date, no study has evaluated the role of
MHR in ISR. We hypothesized that pre-procedural
MHR levels could predict ISR in stable or unstable an-




The study herein is a single-center and retrospectively
analyzed data from 468 consecutive patients who under-
went successful BMS implantation from January 2010 to
December 2013 at our institution. The study was
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approved by the Ethics Commission of Turkiye Yuksek
Ihtisas Training and Research Hospital and was imple-
mented in complete concordance with the Declaration
of Helsinki on human research. Patients who underwent
PCI because of stable or unstable angina pectoris and
successful BMS implantation were included in this study.
Unstable angina pectoris were described according to
the Braunwald classification [10].
Information including gender, age, smoking status,
hyperlipidemia, hypertension, and diabetes mellitus was
gathered. The definition of hypertension appeared as a
systolic blood pressure value of ≥140 mmHg and/or a
diastolic blood pressure value of ≥90 mmHg at least on
>2 office BP measurements or being on an antihyperten-
sive therapy. The definition of the diabetes mellitus com-
prised a blood sugar value of ≥126 mg/dl in the fasting
state or being on an antidiabetic therapy whereas the
status of hyperlipidemia was based on the presence of a
total cholesterol level of ≥200 mg/dl or a triglyceride
level of ≥150 mg/dl in the fasting state. Smoking was de-
fined as current smoking or ex-smokers who forwent
smoking in the past 6 months.
Severe liver disease, renal dysfunction (glomerular fil-
tration rate <90 ml/min/1.73 m2) disease, active infec-
tions, heart failure, thyroid diseases, malignancy,
autoimmune diseases or chronic connective tissue dis-
eases, major surgery, trauma, and alcohol consumption
were excluded from the study.
Biochemical and hematological parameters
As part of our pre-procedural protocol, complete blood
count, and biochemical parameters had already been avail-
able before coronary angiography for all patients. Dry tubes
were used for biochemical analysis, and EDTA tubes were
used for the hematological tests. White blood cell and
erythrocyte counts, hemoglobin along with hematocrit
levels were analyzed by an automated hematology device
Coulter Counter LH Series (Beckman Coulter Inc, Hialeah,
Florida). The biochemical measurements were determined
by an automated analyzer of biochemistry (Abbott Aeroset,
Abbott Laboratories, Abbott Park, Illinois).
Coronary angiography and percutaneous coronary
intervention
Coronary interventions were performed according to
current practice guidelines and recorded in digital stor-
age for further analysis [11]. The degree of coronary sten-
osis was visually estimated by experienced interventional
cardiologists. Luminal narrowing > 50 % in a major sub-
epicardial vessel (left anterior descending, left circumflex,
or right coronary artery) was defined as significant sten-
osis. Target lesions were treated by elective PCI with cor-
onary stent implantation. Only patients received the
study which used BMS during the intervention and all
BMS’s were thin-strut stainless steel stent. Each patient
received 300 mg acetylsalicylic acid plus 300 or 600 mg
clopidogrel before or during coronary intervention. Pa-
tients received weight-adjusted unfractionated heparin
(100 U/kg) before the intervention. Femoral or radial ac-
cess site for intervention was at the physician’s choice.
Use of glycoprotein IIb/IIIa inhibitors and predilatation
or postdilatation after stent implantation of the lesion
was at the operator’s decision. A successful PCI was pre-
viously defined as the achievement of a minimum sten-
osis diameter reduction to <50 % in the presence of
grade-III Thrombolysis in Myocardial Infarction flow
(assessed by angiography) without side branch loss, flow-
limiting dissection, or angiographic thrombus [12]. Dur-
ing routine clinical follow-up, coronary angiography was
performed because of clinical indications in patients with
stable or unstable angina pectoris. Control coronary an-
giograms were recorded using the Judkins technique and
angiographic analysis was performed by two experienced
and blinded interventional cardiologists. In the event of a
disagreement, the assessment was then conducted by a
third interventional cardiologist, and the final analysis
was then considered. The ISR was defined evidence of
stenosis ≥ 50 % either on the site of the previously treated
vessel, inside the stent, or 5 mm proximally or distally to
the previously treated vessel, requiring a new revasculari-
zation procedure of the target lesion [13].
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation and categorical variables were defined as percent-
ages (%). The chi-square test was used for the categorical
variables. Data were tested for normal distribution using
the Kolmogorov-Smirnov test. Continuous variables of nor-
mally disturbed variables were analyzed with an independ-
ent T-test, and continuous variables of non-normally
disturbed variables were analyzed with Mann-Whitney U
test. The Pearson correlation test was used for correlation
analysis.
Predictors of ISR were determined by logistic regression
analysis. Univariate linear regression analysis was used to
evaluate the association of ISR with several biochemical
and hematological parameters. All items with significant
results in univariate analysis were included in multivariate
analysis, followed by a stepwise forward elimination. The
strength of association between variables and the ISR were
represented by odds ratios and their accompanying 95 %
confidence intervals. Receiver operating characteristic
(ROC) curve analysis was used to determine the optimum
cut-off level of pre-procedural MHR values to predict ISR.
Statistical analyses were performed using SPSS 17.0 (SPSS
Inc, Chicago, Illinois). A two-tailed p-value of <0.05 was
regarded as statistically significant.
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Results
In the study population, mean age was 60.3 ± 10.1 years;
clinical and procedural characteristics of the population
according to with ISR and without ISR (n = 225 and 243,
respectively) are summarized in Table 1. The lesion char-
acteristics and angioplasty procedural variables were simi-
lar in both patient groups, except for stent diameter and
time between the two coronary angiographic studies. Pa-
tients with ISR had narrower stent diameter compared
with non-ISR group (2.8 ± 0.35 vs. 2.9 ± 0.35 respectively)
(p = 0.01). The mean time interval from stent implantation
to re-angiogram was 14 ± 7.9 months and the ISR group
had significantly longer period between two coronary an-
giographies compared to non-ISR group (15.9 ± 8.5 vs.
13.1 ± 6.8 months, respectively <0.001 ).
The results of the hematological and biochemical pa-
rameters are listed in Table 2. Biochemical parameters
were similar between groups except for HDL, C-reactive
protein (CRP) and uric acid (UA) levels. Whereas the
HDL levels were lower in ISR group than group non-ISR
group (38.4 ± 9,3 vs. 41.9 ± 11.6) (p < 0.001) , the CRP
(8.2 ± 8.79 vs. 5.8 ± 6.32) (p = 0.007) and UA levels (5.8 ±
1.48vs. 5.2 ± 1.45) (p < 0.001) were higher in ISR group
compared to non-ISR group. The MHR was statistically
higher in ISR group compared to non-ISR group (Fig. 1).
Univariate logistic regression analyses showed that the
stent diameter, the time between the two coronary
angiographic studies, glucose, hemoglobin, CRP, serum
UA and MHR levels were all significantly associated with
ISR. These variables were included in a multivariate re-
gression modeling, which revealed that stent diameter,
the time between the two coronary angiographic studies,
serum UA and MHR levels were independently
Table 1 Basal demographic, clinical and angiographic features







Male, n (%) 158 (65) 171 (76) 0.15
Age (years, mean ± SD ) 60.7 ± 10.0 60 ± 10.2 0.47
Hypertension, n (%) 152 (62) 122 (54) 0.06
Diabetes Mellitus, n (%) 73 (30) 69 (30) 0.88
Hyperlipidemia, n (%) 150 (61) 149 (66) 0.31
Smoke, n (%) 94 (38) 104 (44) 0.09
Left Ventricle Ejection
fraction (%)
56.3 ± 4.5 56.0 ± 5.2 0.46
Target coronary artery, n (%) 0.43
-Left anterior descending 115 (47) 110 (49)
-Left circumflex 76 (31) 50 (22)
-Right 52 (22) 65 (29)
Reason for stent implantation,
n (%)
0.14
-Unstable angina pectoris 174 (72) 147 (65)
-Stable angina pectoris 69 (28) 78 (35)
Number of coronary arteries
narrowed, n (%)
0.08
1 49 (20) 58 (26)
2 165 (68) 148 (66)
3 29 (12) 19 (8)
Stent length (mm, mean ± SD) 15.8 ± 4.4 15.6 ± 4.1 0.60
Stent diameter
(mm, mean ± SD)
2.9 ± 0.35 2.8 ± 0.35 0.01
Time between the 2 coronary
angiographic studies (months,
mean ± SD)
15.9 ± 8.5 13.1 ± 6.8 <0,001
Angiotensin-converting
enzyme inhibitors, n (%)
195 (80) 192 (85) 0.14
Angiotensin receptor blockers,
n (%)
15 (6) 10 (4) 0.40
Beta blockers, n (%) 202 (83) 195 (86) 0.28
Statins, n (%) 209 (86) 190 (84) 0.63
ISR in-stent restenosis, BMS bare-metal stenting, mm millimeter, SD
standart deviation.
Bold data displays statisticially significant difference (p<0.05)
Table 2 Comparison of biochemical and hematological
characteristics in CAD patients undergoing BMS implantation






Glucose, mg/dL, mean ± SD 120 ± 46.0 127 ± 52.5 0.11
Creatinine, mg/dL, mean ± SD 0.88 ± 0.26 0.91 ± 0.23 0.11
Total cholesterol, mg/dL,
mean ± SD
177 ± 43.2 176 ± 43.1 0.77
Triglyceride, mg/dL 150 ± 77.5 164 ± 84.0 0.06
Low-density lipoprotein,
mg/dL, mean ± SD
108 ± 34.9 106 ± 39.0 0.58
High-density lipoprotein,
mg/dL, mean ± SD
41.9 ± 11,6 38.4 ± 9.3 <0.001
Uric Acid, mean ± SD 5.2 ± 1.45 5.8 ± 1.48 <0.001
Hemoglobin, g/dL,
mean ± SD
13.9 ± 1.68 13.8 ± 3.21 0.76
Platelet, ×103/L, mean ± SD 259 ± 74.6 267 ± 69.6 0.18
White blood cell, × 10 9 /μl ,
mean ± SD
7700 ± 1820 9100 ± 1730 <0.001
Neutrophil × 10 9 /μl ,
mean ± SD
4600 ± 1340 6600 ± 1770 <0.001
Lymphocyte ×10 9 /μl ,
mean ± SD
2200 ± 680 1700 ± 540 <0.001
Monocyte ×10 9 /μl ,
mean ± SD
550 ± 250 610 ± 240 0.006
C-reactive protein (mg/dl),
mean ± SD
5.8 ± 6.32 8.2 ± 8.79 0.007
Monocyte/ HDL Ratio 14.1 ± 7.17 16.7 ± 7.95 <0.001
CAD coronary artery disease, ISR instent restenosis, BMS bare-metal stent, HDL
high-density lipoprotein, SD standart deviation, IQR interquantile range.
Bold data displays statisticially significant difference (p<0.05)
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associated with ISR (Table 3). Receiver operating charac-
teristic curves were used to explore the relation between
MHR and ISR. The area under the curve was 0.655
(95 % CI 0.606 to 0.704, p < 0.001). Using a cutoff level
of 14.1, the pre-procedural MHR predicted ISR with a
sensitivity of 66 % and specificity of 61 % (Fig. 2).
Discussion
The present study demonstrated that pre-procedural
MHR levels are higher in patients with ISR compared to
patients without ISR, and that MHR correlates with UA
and CRP levels. Moreover, the MHR was an independent
predictor of ISR on top of high CRP, UA levels, stent
diameter and time between two coronary angiographic
studies. The pre-procedural MHR >14.1 predicted ISR
with a sensitivity of 66 % and specificity of 61 %. This
might reportedly be the first study demonstrating the
link between MHR and bare-metal restenosis in stable
or unstable angina pectoris patients.
The patients with ISR had a higher risk of cardiac death
and MI and that a prolonged regiment of DAPT may re-
duce this risk [14]. Despite new medications and tech-
niques, however, ISR still remains an unresolved problem.
After stent implantation, several processes play roles in
the coronary wall [15]. During stent implantation, mech-
anical vascular damage occurs and triggers inflammation,
followed by smooth muscle cell migration and prolifera-
tion. After that neo-intimal proliferation occurs and finally
this process end with ISR by promoting neo-intimal pro-
liferation through the stent struts [16, 17], particularly in
patients with persistent systemic inflammation or auto-
immune disease. Indeed, the inflammation is associated
with many different diseases or disorders such as
diabetes-associated nephropathy and retinopathy, infec-
tious diseases, rheumatoid arthritis, systemic lupus ery-
thematosus; chronic obstructive pulmonary disease
(COPD); metabolic syndrome, end stage renal disease
Fig. 1 Median MHR values in patients with and without instent restenosis
Table 3 Univariate and multivariate Cox regression analyses for
predictors of bare metal stent restenosis
Variable Univariate analysis Multivariate analysis
HR (95 % CI) p
value
HR (95 % CI) p value
Age 1.00 0.97–1.03 0.977
Male gender 0.59 0.26–1.34 0.209
Hypertension 1.20 0.66–2.17 0.538
Diabetes mellitus 1.92 0.97–3.80 0.060
Smoker 0.76 0.39–1.49 0.436
Stent length 0.96 0.90–1.03 0.296
Stent diameter 0.33 0.15–0.72 0.005 0.42 0.20–0.85 0.017
Time between 2
KAG
0.95 0.91–0.98 0.004 0.94 0.91–0.98 0.002
Glucose 1.00 1.00–1.01 0.018 1.00 099.–1.00 0.180
Creatinine 1.59 0.39–6.34 0.512
HDL 0.97 0.95–1.00 0.155
LDL 1.00 0.99–1.01 0.116
Triglyceride 1.00 0.99–1.00 0.678
LVEF 1.02 0.97–1.08 0.320
Haemoglobin 0.82 0.67–1.00 0.050 0.92 0.78–1.08 0.327
MHR 1.05 1.00–1.11 0.041 1.09 1.04–1.14 <0.001
CRP 1.04 1.00–1.09 0.024 1.03 0.99.–1.07 0.051
Uric acid 1.23 1.01–1.50 0.037 1.24 1.04–1.48 0.014
HDL high density lipoprotein, LDL low density lipoprotein, LVEF left ventricle
ejection fraction, MHR monocyte to HDL cholesterol Ratio, CRP C reactive
protein, HR hazard ratio, CI confidence interval.
Bold data displays statisticially significant difference (p<0.05)
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(ESRD) as well as various cardiovascular diseases or
disorders including atherosclerosis. Moreover, it is well
established that diabetes, ESRD or COPD are comor-
bidities related to higher ISR risk [18]. Therefore; sev-
eral inflammatory markers have been studied in the
prediction of ISR [19–21]. It has been demonstrated in
a metaanalysis that pre-procedural CRP levels were a
significant predictor of ISR after BMS implantation
[22]. The count of circulating monocytes, as the source
of tissue macrophages and foam cells, interact with
platelets and endothelial cells and leading to aggravated
inflammation [4]. Monocyte count has been shown as a
predictor of coronary events [23] and monocyte activa-
tion is a very important step in the beginning of the
atherosclerotic process [24]. HDL cholesterol has anti-
inflammatory, antioxidant, and antithrombotic effects
[25]. HDL is highly effective at inhibiting endothelial
expression of adhesion molecules and preventing
monocyte recruitment to the artery wall [26]. HDL-
cholesterol has a close interaction with monocytes
through suppressing monocyte activities, interrupting
differentiation of monocytes to macrophages which re-
sult in a restricted inflammatory response [27]. There-
fore, it is possible to combine these two parameters
into a single ratio as an MHR, which can reflect the
underlying inflammation process. Indeed, it has been
demonstrated that higher MHR related to worse car-
diovascular events in chronic kidney disease [28] or the
isolated coronary ectasia patients [29]. Canbolat et al.
showed that pre-procedural MHR levels are associated
with atrial fibrillation recurrence after ablation proced-
ure [8]. In a recent study by Cetin et al., MHR was
shown as an independent predictor of stent thrombosis
in STEMI patients [9]. In all studies, the MHR was
associated systemic inflammation and endothelial dys-
function and defined as a novel inflammation-based
prognostic marker in cardiovascular diseases.
It is well known that another important role in the
pathogenesis of ISR is oxidative stress. High levels of re-
active oxygen species produced after PCI and they have
been related to migration and proliferation of smooth
muscle cells and resulted to ISR [30]. The UA is a well-
known oxidative biomarker. Turak et al. demonstrated
that the UA levels are related with ISR after BMS implant-
ation and our findings are consistent with this [31]. In-
deed, the oxidative stress and inflammation are closely
related pathophysiological processes, one of which can be
easily induced by another [32]. Since the role of inflamma-
tion as both a cause and a result of oxidative stress is sup-
ported by a considerable body of evidence, both processes
are simultaneously found in many pathological conditions.
On the other side, while the oxidative stress pathway is
closely related to inflammation, most studies of bio-
markers of oxidative stress do not consider markers of in-
flammation. Therefore, the combining this new MHR
parameter as a “inflammatory marker” with the UA levels
as an “oxidative stress marker” might be used in predicting
of the ISR as a composite measure of oxidative stress- and
inflammation-related restenosis process.
Limitations
There are some limitations of the present study. Enrol-
ment was retrospective and single-center design. The
definition of ISR was based on visual assessment rather
than more quantitative and informative intravascular
ultrasound or optical computed tomographic results.
Specificity and sensitivity of MHR in detecting ISR was
relatively low. Also, other markers of oxidative stress
Fig. 2 Receiver operating characteristic curve pre-procedural MHR and instent restenosis
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and inflammation were not evaluated. This study only
included patients with BMS stents, the findings should
not be generalized to drug eluting stents. Notwithstand-
ing these limitations, this is reportedly the first study fo-
cusing on MHR with regard to its predictive value in
ISR after BMS implantation, and more comprehensive
studies are still warranted to corroborate our findings.
Conclusion
This is the first study to investigate the correlation be-
tween pre-interventional MHR and ISR after BMS im-
plantation in patients with stable or unstable angina
pectoris. Our results indicate that elevated MHR is asso-
ciated with ISR, and showed a correlation between MHR
and markers of inflammation (CRP) and oxidative stress
(uric acid). Because of its wide availability and inexpen-
sive cost for screening, pre-procedural MHR levels may
identify patients at higher risk for ISR and may influence
our clinical management.
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